We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Evidence grows for value of high-field MRI in prostate cancer Rx strategy

  • Karen Sandrick
Apr 24, 2009
Volume: 
18
Issue: 
4
  • Genitourinary Cancers, Prostate Cancer
Abstract / Synopsis: 

ABSTRACT: New treatments for prostate cancer require precise localization of disease, but how to determine which patients are most suitable for these therapies? High-field MRI could be the answe

VIENNA—Image-guided intensity-modulated radiotherapy, high-intensity focused ultrasound, and cryotherapy are increasing the curative treatment options for men with prostate cancer. The problem is how to determine which patients are most suitable for these therapies.

The new treatments for prostate cancer require precise localization of disease, but routinely used imaging techniques are not sensitive or specific enough for accurate staging. Gray-scale transrectal ultrasound has a sensitivity of 30% to 50% and specificity of 77% to 90% for local staging and tumor localization, and 1.5T MRI has a joint sensitivity and specificity of 71% to 74% for conventional anatomical prostate imaging, according to recent research.

High-field MRI could be the answer, according to a special focus session at the European Congress of Radiology 2009 (ECR SF1B).

“MR is a powerful method for imaging the prostate gland because its high spatial resolution provides excellent soft-tissue contrast, which may aid the detection and localization of malignant lesions, the evaluation of disease stage based on the extraprostatic extension of cancer, and the detection of local or distant disease recurrence after treatment,” said Jurgen J. Ftterer, MD, PhD, of the department of radiology at Radboud University Nijmegen Medical Centre in the Netherlands.

What 3T MRI adds
The signal-to-noise ratio increases almost linearly with magnetic field strength, whereas the noise remains nearly unchanged with 3T MRI. Thus, the SNR is approximately two times higher at 3T compared with 1.5T. The most significant benefit of this difference is the increase of spatial resolution, which improves the depiction of anatomical details and/or shortens acquisition time, thereby increasing patient throughput, Dr. Ftterer explained.

The chemical shift effect also increases linearly with magnetic field strength. Spectral resolution at 3T is therefore enhanced compared with 1.5T. Signal intensity and frequency dispersion are higher, which may lead to better tumor characterization. In dynamic contrast-enhanced MR imaging, the increase in SNR can be used to improve the temporal resolution of dynamic measurements. Increased temporal resolution may improve the accuracy of measurement of pharmacokinetic parameters.

Endorectal 3T T2-weighted and high spatial resolution dynamic contrast-enhanced MRI are able to identify morphological and vascular details, which may guide not only the detection and staging of disease but the direction of biopsies and treatment.

Signal intensity changes obtained during dynamic image acquisition provide an estimate of the amount of contrast material that has accumulated in lesions.

The passage of contrast into and out of lesions reflects the kinetic properties of tissue physiology, such as Ktrans and Ve values, and provides an indication of microvascular permeability and angiogenetic potential, according to B. Nicolas Bloch, MD, who discussed MR perfusion and high-resolution imaging. Dr. Bloch is an instructor in radiology at Beth Israel Deaconess Medical Center in Boston.

The high field strength of 3T MRI is particularly useful in dynamic contrast-enhanced studies of the prostate gland. “Dynamic contrast-enhanced MRI makes it possible to combine fast imaging—less than three seconds per image set—with good spatial resolution. This technique directly benefits from the increased SNR at 3T,” Dr. Ftterer said.

Drawbacks
High-field MRI has its drawbacks and challenges, however, including a quadrupling of radiofrequency power deposition compared with 1.5T, shorter T2- and longer T1-relaxation times, increased susceptibility differences, dielectric effect, and signal heterogeneity from larger B1 field variations. Using thinner slices and increasing the spatial resolution or bandwidth at a higher field may partially circumvent some of these issues, but these changes will offset some of the SNR increase gained with 3T imaging.

In addition, the loss in SNR is less than linear with voxel size due to the decreasing line width (e.g., when resolution is increased from 0.075 to 0.094 cm3, the SNR decreases between 44% and 60%). Due to radiofrequency penetration effects, it can be difficult to achieve good RF field homogeneity. Parallel imaging techniques, increased TR, reduced flip angle, and increased RF pulse duration can be used to overcome these problems, but at the expense of SNR.

Despite these difficulties, the increase in SNR provided by 3T MRI is likely to expand the potential clinical applications for evaluating the prostate, Dr. Ftterer said.

“Endorectal 1.5T MRI is a common method of evaluating men with suspected prostate cancer. But in the next few years, 3T MRI will become the standard. An SNR at 3T that is equal to the SNR at 1.5T with an endorectal coil is a big advantage,” he said.

 

Related Articles

  • Nivolumab/Ipilimumab Combo Approved for Advanced RCC
  • No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Pembrolizumab Offers Better QOL vs Chemo in Advanced Urothelial Cancer
  • First-Line Avelumab/Axitinib Encouraging in Advanced RCC

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.